DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy.
BMC cancer
Authors:
Olga Grishina, Claudia Schmoor, Caroline Sellner, Björn Hackanson, Jan-Henrik Mikesch, Iordanis Deligiannis, Felicitas Thol, Martina Crysandt, Christian Junghanss, Volker Runde, Paul La Rosée, Lino Lars Teichmann, Haifa Kathrin Al-Ali, Tim Sauer, Ulrich Germing, Frank Griesinger, Stefan Lukic, Jürgen Krauter, Snjezana Janjetovic, Jan Koch, Peter Staib, Julian Topaly, Maike de Wit, Doris Maria Kraemer, Lorenz Oelschläger, Ulf Schnetzke, Oliver Schmah, Swen Wessendorf, Cyrus Khandanpour, Lukas Kündgen, Monika Schwalenberg, Michael Heuser, Arnold Ganser, Hartmut Döhner, Ralph Wäsch, Michael Lübbert
Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).
Leukemia
Authors:
Andreas Burchert, Franck E Nicolini, Philipp le Coutre, Susanne Saussele, Andreas Hochhaus, Evin Tuere, Stephan K Metzelder, Kim Pauck, Holger Garn, Hartmann Raifer, Magdalena Huber, Norbert Gattermann, Martina Crysandt, Philippe Schafhausen, Matthias Bormann, Markus P Radsak, Agnès Guerci-Bresler, Thomas Illmer, Maria E Goebeler, Peter Herhaus, Lino L Teichmann, Georg-Nikolaus Franke, Fabian Lang, Stefan W Krause, Robert Möhle, Martine Klausmann, Frank Stegelmann, Christoph Lutz, Gabriel Etienne, Andrea Stoltefuß, Joachim R Göthert, Thomas Ernst, Maisun Abu-Samra, Heinz-Gert Höffkes, Andreas Neubauer, Ying Wang, Paul Weiland, Clara Otto, Lea Kiessler, Theresa Weber, Lea Kroning, Andrea Nist, Thorsten Stiewe, Rüdiger Hehlmann, Behnaz Aminossadati, Michael Wittenberg, Kerstin Winterstein, Thomas Oellerich, Marcus Lechner, Markus Pfirrmann, Carmen Schade-Brittinger, Paul Klemm, Christian Michel
Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.
Blood
Authors:
Hartmut Döhner, Daniela Späth, Maral Saadati, Walter Fiedler, Katharina S Götze, Elisabeth Koller, Jörg Westermann, Wichard Vogel, Michael Heuser, Michael Lübbert, Hans-Joachim Tischler, Ulrich Germing, Lino Lars Teichmann, Lars Fransecky, Albert Wölfler, David Nachbaur, Bernd Hertenstein, Roland Schroers, Uwe M Martens, Stephanie von Harsdorf, Markus P Radsak, Gregor Aschauer, Stefanie Weißhaar, Andrea Corbacioglu, Anika Schrade, Verena I Gaidzik, Felicitas R Thol, Peter Paschka, Lars Bullinger, Axel Benner, Konstanze Döhner, Arnold Ganser
Frequent and clinically relevant germline DNA repair gene variants in young and familial myeloproliferative neoplasms.
Blood cancer journal
Authors:
Robert Meyer, Maria Jimena Rodriguez, Madeline Caduc, Kim Kricheldorf, Matthias Begemann, Florian Kraft, Isabel Spier, Daniela Dey, Nergis Güzel, Kerstin Becker, Julian Baumeister, Marcelo A S de Toledo, Susanne Isfort, Ulrich Germing, Stefan Aretz, Tim H Brümmendorf, Ingo Kurth, Miriam Elbracht, Lino L Teichmann, Steffen Koschmieder
NLRP3-induced systemic inflammation controls the development of JAK2V617F mutant myeloproliferative neoplasms.
Nature communications
Authors:
Ruth-Miriam Koerber, Calvin Krollmann, Kevin Cieslak, Elisabeth Tregel, Maria L Saenz, Tim H Brümmendorf, Steffen Koschmieder, Martin Griesshammer, Ines Gütgemann, Conny K Baldauf, Thomas Fischer, Peter Brossart, Carl Christian Kolbe, Eicke Latz, Dominik Wolf, Lino L Teichmann
Tissue inflammation induced by constitutively active STING is mediated by enhanced TNF signaling.
eLife
Authors:
Hella Luksch, Felix Schulze, David Geißler-Lösch, David Sprott, Lennart Höfs, Eva M Szegö, Wulf Tonnus, Stefan Winkler, Claudia Günther, Andreas Linkermann, Rayk Behrendt, Lino L Teichmann, Björn H Falkenburger, Angela Rösen-Wolff
MoReLife - real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients.
Annals of hematology
Authors:
Stefanie Jilg, Juliana Schwaab, Katja Sockel, Carl C Crodel, Valeska Brueckl, Frank Stegelmann, Madlen Jentzsch, Daniel Sasca, Margarete Moyses, Stephan Fuhrmann, Daniel Gundel, Madlen Caduc, Lino L Teichmann, Florian Heidel, Haifa K Al-Ali, Petro E Petrides
Refinement of the prognostic impact of somatic bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG).
HemaSphere
Authors:
Frank G Rücker, Andrea Corbacioglu, Julia Krzykalla, Sibylle Cocciardi, Claudia Lengerke, Ulrich Germing, Gerald Wulf, Maisun A Samra, Lino L Teichmann, Michael Lübbert, Michael W M Kühn, Martin Bentz, Jörg Westermann, Lars Bullinger, Verena I Gaidzik, Annika Meid, Sophia Aicher, Frank Stegelmann, Daniela Weber, Anika Schrade, Felicitas Thol, Michael Heuser, Arnold Ganser, Axel Benner, Hartmut Döhner, Konstanze Döhner
Platelet transcription factors license the pro-inflammatory cytokine response of human monocytes.
EMBO molecular medicine
Authors:
Ibrahim Hawwari, Lukas Rossnagel, Nathalia Rosero, Salie Maasewerd, Matilde B Vasconcelos, Marius Jentzsch, Agnieszka Demczuk, Lino L Teichmann, Lisa Meffert, Damien Bertheloot, Lucas S Ribeiro, Sebastian Kallabis, Felix Meissner, Moshe Arditi, Asli E Atici, Magali Noval Rivas, Bernardo S Franklin
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study.
Annals of hematology
Authors:
Susanne Isfort, Kirsi Manz, Lino L Teichmann, Martina Crysandt, Andreas Burchert, Andreas Hochhaus, Susanne Saussele, Alexander Kiani, Joachim R Göthert, Thomas Illmer, Philippe Schafhausen, Haifa Kathrin Al-Ali, Frank Stegelmann, Mathias Hänel, Tim Pfeiffer, Aristoteles Giagounidis, Georg-Nikolaus Franke, Steffen Koschmieder, Alice Fabarius, Thomas Ernst, Mareille Warnken-Uhlich, Uta Wolber, Denise Kohn, Markus Pfirrmann, Dominik Wolf, Tim H Brümmendorf